Briumvi™ (ublituximab-xiiy) Intravenous Injection

Covered: Briumvi (ublituximab-xiiy) IV is authorized for adults (≥18 years) with relapsing forms of MS (clinically isolated syndrome, relapsing‑remitting MS, active secondary progressive MS); other forms (e.g., primary progressive) are not specified as covered. Key requirements: prescriber must be or consult a neurologist/MS specialist, approvals are time‑limited to 12 months with dosing of 150 mg (first), 450 mg at 2 weeks, then 450 mg every 24 weeks, and reauthorization requires ≥12 months on Briumvi with documentation of clinical benefit or stabilization (e.g., MRI, EDSS, NEDA metrics, relapse reduction or functional improvement) and adherence to the dosing schedule.

"Briumvi is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease,..."